MicroRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer

British Journal of Cancer

Volumn 108, Issue 8, 2013, Pages 1659-1667

  Ueno, K ^a   Hirata, H ^a   Shahryari, V ^a   Deng, G ^a   Tanaka, Y ^a   Tabatabai, Z L ^b   Hinoda, Y ^c   Dahiya, R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DKK 3 PROTEIN; MICRORNA; MICRORNA 146A; MICRORNA 183; PROSTATE SPECIFIC ANTIGEN; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR GROWTH; UPREGULATION;

BETA CATENIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; IN SITU HYBRIDIZATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; SMAD4 PROTEIN; TRANSFECTION; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84877074727     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.125     Document Type: Article

References (31)

1. Abarzua F, Sakaguchi M, Takaishi M, Nasu Y, Kurose K, Ebara S, Miyazaki M, Namba M, Kumon H, Huh NH (2005) Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. Cancer Res 65: 9617-9622.
2. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170.
3. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M, Garća-Foncillas J (2006) Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5: 29.
4. Chan JM, Holick CN, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Giovannucci EL (2006) Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 17: 199-208.
5. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG (2001) Risk of prostate carcinoma death in patients with lymph nodemetastasis. Cancer 91: 66-73.
6. Cho WC, Chow AS, Au JS (2009) Restoration of tumour suppressor hsamiR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer 45: 2197-2206.
7. de Winter JP, Roelen BA, ten Dijke P, van der Burg B, van den Eijnden-van Raaij AJ (1997) DPC4 (SMAD4) mediates transforming growth factorbeta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 14: 1891-1899.
8. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA (2011) SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470: 269-273.
9. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353.
10. Horvath LG, Henshall SM, Kench JG, Turner JJ, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Sutherland RL (2004) Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate 59: 234-242.
11. Ijichi H, Otsuka M, Tateishi K, Ikenoue T, Kawakami T, Kanai F, Arakawa Y, Seki N, Shimizu K, Miyazono K, Kawabe T, Omata M (2004) Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta. Oncogene 23: 1043-1051.
12. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
13. Kawano Y, Kitaoka M, Hamada Y, Walker MM, Waxman J, Kypta RM (2006) Regulation of prostate cell growth and morphogenesis by Dickkopf-3. Oncogene 25: 6528-6537.
14. Labbé E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, Moses HL, Attisano L (2007) Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res 67: 75-84.
15. Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, Qin Y, Sun Z, Zheng X (2010) miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer 10: 354.
16. Liu R, Zhou Z, Huang J, Chen C (2011) PMEPA1 promotes androgen receptor-negative prostate cell proliferation through suppressing the Smad3/4-c-Myc-p21 Cip1 signaling pathway. J Pathol 223: 683-694.
17. Lu W, Tinsley HN, Keeton A, Qu Z, Piazza GA, Li Y (2009) Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol 602: 8-14.
18. MacGrogan D, Pegram M, Slamon D, Bookstein R (1997) Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 15: 1111-1114.
19. McManus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3: 737-747.
20. Mihelich BL, Khramtsova EA, Arva N, Vaishnav A, Johnson DN, Giangreco AA, Martens-Uzunova E, Bagasra O, Kajdacsy-Balla A, Nonn L (2011) miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem 286: 44503-44511.
21. Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27: 1788-1793.
22. Pienta KJ, Esper PS (1993) Risk factors for prostate cancer. Ann Intern Med 118: 793-803.
23. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135.
24. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597.
25. Roemeling S, Roobol MJ, de Vries SH, Gosselaar C, van der Kwast TH, Schröder FH (2006) Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. J Urol 175: 1332-1336.
26. Sarver AL, Li L, Subramanian S (2010) MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res 70: 9570-9580.
27. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166-1176.
28. Shukla S, Gupta S (2005) Dietary agents in the chemoprevention of prostate cancer. Nutr Cancer 53: 18-32.
29. Ueno K, Hirata H, Shahryari V, Chen Y, Zaman MS, Singh K, Tabatabai ZL, Hinoda Y, Dahiya R (2011) Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma. Br J Cancer 104: 308-315.
30. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261.
31. Ying SY, Chang DC, Lin SL (2008) The microRNA (miRNA): overview of the RNA genes that modulate gene function. Mol Biotechnol 38: 257-268.